Navigation Links
Agent selectively targets malignant B cells in chronic leukemia, study shows
Date:5/3/2011

COLUMBUS, Ohio A new experimental drug selectively kills the cancerous cells that cause chronic lymphocytic leukemia, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

The study shows that the experimental agent PCI-32765 selectively kills the malignant B lymphocytes that cause chronic lymphocytic leukemia (CLL).

The researchers say the findings, published online in the journal Blood, are important because current CLL therapies kill T lymphocytes along with the cancerous B lymphocytes.

T lymphocytes and B lymphocytes make up the adaptive immune system. When CLL treatment destroys them both, patients become highly susceptible to life-threatening infections.

"A drug that kills malignant B lymphocytes and spares T lymphocytes could dramatically improve outcomes for CLL patients," says study leader Dr. John C. Byrd, director, division of hematology and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC James.

"Our collective results indicate that PCI-32765 is an outstanding candidate for further development as a therapeutic for CLL," says study co-director Dr. Amy J. Johnson, assistant professor of hematology and medicinal chemistry, and a CLL researcher with the OSUCCC-James.

The research by Byrd, Johnson and a group of colleagues used CLL cells from ten patients. It had several key findings related to PCI-32765:

  • The agent specifically targets an important signaling molecule called Bruton's tyrosine kinase, which is overexpressed in CLL cells and absent in T cells.
  • The agent inhibits the proliferation of CLL cells in laboratory culture and promotes their death by self-destruction (apoptosis).
  • It blocks survival signals from cells in the surrounding microenvironment, including soluble factors such as IL-6, IL-4, and TNF-α, and stromal-cell contact.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Professional Insurance Agents to Hold 2010 Federal Legislative Summit March 17-18
2. Long Term Care Insurance Leader Seeks 320 New Agents in 2010, Following Strong 2009 Growth
3. Professional Insurance Agents Name Rep. Charlie Melancon 2010 Legislator of the Year
4. Overcoming tumor resistance to anti-cancer agent TRAIL
5. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
6. Targeted agent blocked growth of deadly brain cancer in preclinical studies
7. New agent chokes off energy supply, kills cancer cells
8. Health Insurance Agents Work with Zane Benefits to Offer New Solutions amid Health Care Reform
9. Mayo-led research team develop agents that keep insulin working longer
10. Shark cartilage shows no benefit as a therapeutic agent for lung cancer
11. Compound enhances cancer-killing properties of agent in trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, a ... its 60-day free trial program for all of the company’s desktop riser products. ... truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced dual ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame ... (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking ... prescription drug plan (Part D) need to make changes during this period order for ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs available ... must find the one that works for them. When an inventor from Suisun City, ... worked and decided to share it with others. , He developed a prototype for ...
(Date:12/2/2016)... Hills, CA (PRWEB) , ... December 02, 2016 ... ... reconstructive surgeon in Beverly Hills, California, will be included in the 2016 “Guide ... given to exceptional professionals based on the amalgamation of their education, experience, and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is ... USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that ... “We are prolonging life 6 years in the last 3 decades,” says Dr. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Va. , Dec. 2, 2016  The ... by the Academy of Managed Care Pharmacy (AMCP), ... organizations can better address the opioid addiction crisis, ... Assisted Therapies (MAT). ATAG,s newly released ... Improving Access to Naloxone," addresses many issues around ...
(Date:12/2/2016)... Dec. 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), ... Specialties, Inc. ("PSI").  The combination of Texas ... -based PSI bring together both company,s clinical expertise and ... payers an industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... 2, 2016 CVS Health Corporation (NYSE: ... in New York City on Thursday, December 15, 2016, beginning at 8:00 a.m. ... will provide an in-depth review of the company,s strategies ... company will also discuss 2017 earnings guidance during the ... the event will be broadcast simultaneously on the Investor ...
Breaking Medicine Technology: